This is a randomised, double-blind, placebo-controlled, parallel group, multi-center, multi-national, Phase II/III study to assess the efficacy and safety of three different doses regimens of Oralgen Grass Pollen in patients with grass pollen-related allergic rhinoconjnctivitis.
Laufzeit: 01.01.2007 - 31.12.2008
imported
Kurzfassung
Healthy male or female patients aged 18 to 50 years with a documented history of seasonal grass pollen-related rhinoconjunctivitis will be randomised to one of four treatment groups.
